Publications by authors named "Christof Schindler"
Article Synopsis
- The field of therapeutic antibodies, particularly bi- or multispecific antibodies, is expanding rapidly, especially for cancer treatment due to their ability to target multiple pathways.
- Designing and creating multispecific antibodies is complex and labor-intensive, starting with generating antibodies against specific targets and then combining their binding sites, as suitable configurations are hard to predict.
- The SpyTag-SpyCatcher technology allows for easier assembly of these multispecific antibodies by enabling separate production of tag and catcher proteins, and experiments have successfully created large multivalent antibodies containing up to seven building blocks while maintaining binding functionality.
Background: In elderly patients with HER2-positive breast cancer, few data on efficacy and toxicity of adjuvant trastuzumab treatment exists since older patients were in general excluded from large randomized studies. This prospective observational study aimed to confirm the beneficial findings from pivotal trials in age cohorts ≥65 years.
Materials And Methods: There were no restrictions for recruitment with respect to age or concomitant/sequential adjuvant medication.